Johns Hopkins spinout Blade Therapeutics has agreed to a reverse merger that will net it $24.3m in Pipe financing from backers including Osage University Partners.
Blade Therapeutics, a US-based fibrosis treatment developer spun out from Johns Hopkins University, has agreed to a reverse merger with special purpose acquisition company Biotech Acquisition Company.
The merger is expected to occur in the first quarter of 2022, whereupon Biotech Acquisition Company will be rebranded to Blade Biotherapeutics and list on Nasdaq using the ticker symbol BBTX.
Osage University Partners is among the investors who are anchoring a $24.3m private investment in public equity deal, as are Deerfield Management,…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
